Dabrafenib Mesylate
BRAF kinase carrying the V600E or V600K substitution signals constitutively through the RAS/MAPK pathway, and dabrafenib mesylate inhibits that altered kinase. Interrupting the pathway removes the proliferative drive in tumours defined by the mutation, which is why treatment is restricted to disease confirmed to carry it. Approved applications span metastatic melanoma, non-small cell lung cancer and anaplastic thyroid carcinoma with BRAF mutation. The mesylate salt improves the pharmaceutical properties of the compound without changing its kinase selectivity. The salt is recorded with the formula C24H24F3N5O5S3 and a mass close to 615.7 g/mol, and it is approved with development completed through the final phase.
The mesylate salt form of dabrafenib, a BRAF V600E/K inhibitor used for treating metastatic melanoma, NSCLC, and anaplastic thyroid cancer with BRAF mutations. The mesylate salt improves the compound's pharmaceutical properties.
Moleküler Ağırlık
615,7000 g/mol
TPSA
210,00 Ų
Terapötik Alanlar
Etki Mekanizması
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
InChI
InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
Molecular Formula
C24H24F3N5O5S3
HBD / HBA
3 / 14
Döndürülebilir Bağlar
6
Ağır Atomlar
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
The mesylate salt form of dabrafenib, a BRAF V600E/K inhibitor used for treating metastatic melanoma, NSCLC, and anaplastic thyroid cancer with BRAF mutations. The mesylate salt improves the compound's pharmaceutical properties.
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Yes, Dabrafenib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105729. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44516822. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dabrafenib-mesylate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dabrafenib-mesylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dabrafenib-mesylate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dabrafenib-mesylate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dabrafenib-mesylate"></drugfyi-drug>